An Open-Label, Multicenter, Long-Term Treatment Extension Study in Sub
Research payments
$687,124
Through program year 2025, $687,124 in research payments was reported against An Open-Label, Multicenter, Long-Term Treatment Extension Study in Sub, across 191 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $79,824 | 50 |
| 2024 | Research | $63,005 | 43 |
| 2023 | Research | $170,347 | 48 |
| 2022 | Research | $254,253 | 41 |
| 2021 | Research | $119,696 | 9 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Veena John New Hyde Park, NY Named on 29 payments
- Nana Tchabo Morristown, NJ Named on 10 payments
- Antoinette Tan Charlotte, NC Named on 10 payments
- Alberto Bessudo Encinitas, CA Named on 9 payments
- Joseph Buscema Tucson, AZ Named on 7 payments
- Meaghan Tenney Atlanta, GA Named on 7 payments
- Heather Parsons Boston, MA Named on 6 payments
- Bobbie Rimel West Hollywood, CA Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.